These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39424599)

  • 21. A comparison of the activity, lysosomal stability, and efficacy of legumain-cleavable and cathepsin-cleavable ADC linkers.
    Gray ME; Zielinski KM; Xu F; Elder KK; McKay SJ; Ojo VT; Benjamin SR; Yaseen AA; Brooks TA; Tumey LN
    Xenobiotica; 2024 Aug; 54(8):458-468. PubMed ID: 38738708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates.
    Watanabe T; Arashida N; Fujii T; Shikida N; Ito K; Shimbo K; Seki T; Iwai Y; Hirama R; Hatada N; Nakayama A; Okuzumi T; Matsuda Y
    J Med Chem; 2024 Oct; 67(20):18124-18138. PubMed ID: 39410752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.
    McCombs JR; Owen SC
    AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells.
    Olatunji FP; Savoy EA; Panteah M; Mesbahi N; Abbasi A; Talley CM; Lovingier CL; Caromile LA; Berkman CE
    Bioconjug Chem; 2021 Nov; 32(11):2386-2396. PubMed ID: 34699177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mono-amino acid linkers enable highly potent small molecule-drug conjugates by conditional release.
    Zheng Y; Xu R; Cheng H; Tai W
    Mol Ther; 2024 Apr; 32(4):1048-1060. PubMed ID: 38369752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-Immolative Linkers Literally Bridge Disulfide Chemistry and the Realm of Thiol-Free Drugs.
    Riber CF; Smith AA; Zelikin AN
    Adv Healthc Mater; 2015 Aug; 4(12):1887-90. PubMed ID: 26109168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conjugation of Doxorubicin to siRNA Through Disulfide-based Self-immolative Linkers.
    Gauthier F; Bertrand JR; Vasseur JJ; Dupouy C; Debart F
    Molecules; 2020 Jun; 25(11):. PubMed ID: 32545345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
    Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linker Architectures as Steric Auxiliaries for Altering Enzyme-Mediated Payload Release from Bioconjugates.
    Giese M; Davis PD; Woodman RH; Hermanson G; Pokora A; Vermillion M
    Bioconjug Chem; 2021 Oct; 32(10):2257-2267. PubMed ID: 34587447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cleavable linkers in antibody-drug conjugates.
    Bargh JD; Isidro-Llobet A; Parker JS; Spring DR
    Chem Soc Rev; 2019 Aug; 48(16):4361-4374. PubMed ID: 31294429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aptamer-Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells.
    Qi J; Zeng Z; Chen Z; Nipper C; Liu X; Wan Q; Chen J; Tung CH; Zu Y
    Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy.
    Wang Y; Fan S; Xiao D; Xie F; Li W; Zhong W; Zhou X
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31288450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.
    Burke PJ; Hamilton JZ; Pires TA; Setter JR; Hunter JH; Cochran JH; Waight AB; Gordon KA; Toki BE; Emmerton KK; Zeng W; Stone IJ; Senter PD; Lyon RP; Jeffrey SC
    Mol Cancer Ther; 2016 May; 15(5):938-45. PubMed ID: 26944920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
    Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P
    Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker.
    Suzawa T; Nagamura S; Saito H; Ohta S; Hanai N; Kanazawa J; Okabe M; Yamasaki M
    J Control Release; 2002 Feb; 79(1-3):229-42. PubMed ID: 11853934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and Synthesis of Isoquinolidinobenzodiazepine Dimers, a Novel Class of Antibody-Drug Conjugate Payload.
    Smith SW; Jammalamadaka V; Borkin D; Zhu J; Degrado SJ; Lu J; Huang J; Jiang YP; Jain N; Junutula JR
    ACS Med Chem Lett; 2018 Jan; 9(1):56-60. PubMed ID: 29348812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification.
    Su D; Kozak KR; Sadowsky J; Yu SF; Fourie-O'Donohue A; Nelson C; Vandlen R; Ohri R; Liu L; Ng C; He J; Davis H; Lau J; Del Rosario G; Cosino E; Cruz-Chuh JD; Ma Y; Zhang D; Darwish M; Cai W; Chen C; Zhou H; Lu J; Liu Y; Kaur S; Xu K; Pillow TH
    Bioconjug Chem; 2018 Apr; 29(4):1155-1167. PubMed ID: 29481745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate.
    Mohamed Amar IA; Huvelle S; Douez E; Letast S; Henrion S; Viaud-Massuard MC; Aubrey N; Allard-Vannier E; Joubert N; Denevault-Sabourin C
    Eur J Med Chem; 2022 Feb; 229():114063. PubMed ID: 34974337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ADME and Safety Aspects of Non-cleavable Linkers in Drug Discovery and Development.
    Walles M; Connor A; Hainzl D
    Curr Top Med Chem; 2017; 17(32):3463-3475. PubMed ID: 29357804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker.
    Liubomirski Y; Tiram G; Scomparin A; Gnaim S; Das S; Gholap S; Ge L; Yeini E; Shelef O; Zauberman A; Berger N; Kalimi D; Toister-Achituv M; Schröter C; Dickgiesser S; Tonillo J; Shan M; Deutsch C; Sweeney-Lasch S; Shabat D; Satchi-Fainaro R
    J Control Release; 2024 Mar; 367():148-157. PubMed ID: 38228272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.